Cancer Research and Clinical Trials at St. Vincent’s

St. Vincent’s Medical Center is committed to medical education and clinical research. It is our hope to create new benchmarks that help all members of our community to improve their health and well-being. 

The Elizabeth M. Pfriem SWIM Center for Cancer Care at St. Vincent’s has numerous ongoing clinical trials that explore innovative treatments that advance our standards of care.

Several clinical trials are offered to patients who may have exhausted currently available treatments for their cancers. Participation in a clinical trial provides you or your loved ones with a unique dual opportunity to aid yourself and others while joining forces with us to win the war on cancer. To learn more, please call (203) 576-6329.


Areas of Research

St. Vincent’s medical researchers seek answers to scientific questions that ultimately result in providing better opportunities to prevent, diagnose and treat cancer. Areas of research include lung, breast, ovarian, pancreas, gastrointestinal, hematologic (blood), head and neck, primary brain tumors, metastatic disease and cancer survivorship.


Types of Clinical Trials

The following define types of clinical trials at St. Vincent’s:

  • Pre-clinical studies: These studies yield chemical or treatment strategies that look promising in the lab.

  • Phase 1 studies: These studies are aimed at learning how to administer treatments to patients in a safe manner. Patients benefit by being able to access treatments that are not broadly available. The medical community learns how to dose these medications, and their efficacy.

  • Phase 2 studies: These studies use dosages of medications determined in Phase 1 studies to treat a defined population of patients and to assess the relative efficacy of a given strategy for a specific cancer.

  • Phase 3 studies: These studies test the strategies derived from Phase 2 trials against the current standard of care, often in a randomized fashion so that no bias enters into the decision regarding which is the best treatment. The results of Phase 3 trials can change how doctors treat all of their patients.

  • Phase 4 studies: These studies permit physicians to better understand the risks associated with these treatments in the real world, as opposed to under carefully controlled clinical trial conditions. Cancer treatment can be divided into initial or up-front treatment, and treatment at relapse, known as salvage, or second and later lines of therapy.

  • Prevention trials: These trials test new approaches, such as medicines, vitamins, minerals or other supplements that doctors believe may lower the risk of a certain type of cancer, while seeking to prevent cancer in people who have never had cancer or a new cancer from presenting in people who have already had cancer.

  • Treatment trials: These trials test new treatments (for example, a new cancer drug, new approaches to surgery or radiation therapy, new combinations of treatments, or new methods such as gene therapy).

  • Screening trials: These trials test the best way to discover the presence of cancer, especially in its early stages.

  • Quality of Life trials: These trials, also called Supportive Care trials, explore ways to improve comfort and quality of life for cancer patients.


Open Clinical Trials

If you or a loved one is considering enrolling in a clinical trial at The Elizabeth M. Pfriem SWIM Center for Cancer Care at St. Vincent’s Medical Center, please consult with your physician regarding the current status of a specific trial and to determine if you are a candidate.

Breast Cancer
  • NRG-BR003/SVMC 15-303: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (PI: Dr. Paul Berard)  

  • NSABP B-55/BIG 6-13: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (PI: Dr. Paul Berard) 

Diffuse Large B-Cell Lymphoma
  • UTX-TGR-2-5/SVMC 16-320: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma (PI: Paul Berard, MD)

Lung Cancer
  • CALGB 140503/SVMC 166: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2cm) Peripheral Non-Small Cell Lung Cancer (NSCLC) (PI: Dr. Brian Solomon) 

  • NRG-CC003/SVMC 15-302: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer (PI: Dr. Nicholas Blondin) 

Gastrointestinal Cancer 
  • RTOG 1112/SVMC 13-255: Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma (PI: Dr. Christopher Iannuzzi) 

  • RTOG 0848/SVMC 11-211: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (PI: Dr. Christine Van Cott) 

Ovarian Cancer 
  • GOG 0213/SVMC 14-262: A Phase III Randomized Controlled Clinical Trial Of Carboplatin and Paclitaxel (Or Gemcitabine) Alone Or In Combination With Bevacizumzb (NSC #704865, IND #113912) Followed by Bevacizumab And Secondary Cytoreductive Surgery In Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary And Fallopian Tube Cancer (PI: Dr. Paul Berard) 

Brain Cancer 
  • RTOG 1470/SVMC 14-267: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC#725085, Alliance IND# 15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiform (GBM) (PI: Dr. Nicholas Blondin) 

Chronic lymphocytic leukemia (CLL) 
  • UTX-IB-301/SVMC 15-282: A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) (PI: Dr. Paul Berard) 

  • UTX-TGR-304/SVMC 16-305: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) (PI: Dr. Paul Berard) 

Head and Neck Cancer
  • RTOG 0920/ SVMC 10-203: Phase III of Post-Operative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer (PI: Dr. Christopher Iannuzzi) 

Brain Mets
  • NRG-CC001/SVMC 15-300: A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Patients with Brain Metastasis (PI: Dr. Nicholas Blondin) 

Cancer Survivorship
  • GOG 0225/SVMC 14-262: Can diet and exercise modulate ovarian, fallopian tube and primary peritoneal cancer progression-free survival? (PI: Dr. Paul Berard) 

Multiple Myeloma